Who founded Omeicos Therapeutics?

Omeicos Therapeutics was founded by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, John R. Falck in 2013.

Who are Omeicos Therapeutics's investors?

Omeicos Therapeutics's investors include Remiges Ventures, Inc., Forbion, Vesalius Biocapital Partners.

Where is Omeicos Therapeutics headquartered?

Omeicos Therapeutics is headquartered in Berlin, DE.

Omeicos Therapeutics

Berlin, DE · Founded 2013 · 9 employees on LinkedIn · 3 known investors

Find your way into Omeicos Therapeutics

18 people in our graph share verified history with the Omeicos Therapeutics team — schools, employers, funds. One of them is your warm intro.

Ute Merckerunlockedknows Robert Fischer · together at Omeicos Therapeutics (overlapped)

×2knows the team · via Omeicos Therapeutics

×6knows the team · via Charité

×3knows the team · via Max Delbrück Center

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.

Biotech Healthtech

Founders & leadership

Omeicos Therapeutics was founded in 2013 by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, and John R. Falck.

Robert Fischer inCEO/CSO & Co-FounderRobert Fischer is CEO and Chief Scientific Officer of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular and mitochondrial diseases. He has expertise in cardiology and cardiac arrhythmias, holds board certification in internal medicine, and has authored over 20 publications and contributed to 2 patents.

Karen Uhlmann inVice President Operations & IP, Co-FounderKaren Uhlmann is Vice President of Operations & IP and Co-Founder of Omeicos Therapeutics, a biotech company developing small-molecule therapeutics for cardiovascular, inflammatory, and rare mitochondrial diseases. She has experience in technology transfer and serves as an expert advisor for research funding and startup evaluation bodies in Europe.

Wolf-Hagen SchunckCo-Founder

John R. FalckCo-Founder

Investors · 3

Remiges Ventures, Inc.✓ verifiedSeattle

Forbion✓ verifiedNaarden

Vesalius Biocapital PartnersLuxembourg · $11M

In the news

German biopharma company Omeicos Therapeutics snags Series C fundingventurecapitaljournal.com · Nov 2018

Forbion leads €17m series-C for Omeicos | Unquoteunquote.com · Nov 2018

Omeicos raises €17M to run phase 2 atrial fibrillation trial | Fierce Biotechfiercebiotech.com · Nov 2018

Omeicos Raises Series B Financing Round Extension - FinSMEsfinsmes.com · Oct 2017

Omeicos Therapeutics Raises €6.2M in Series A Funding | FinSMEsfinsmes.com · Apr 2015

Frequently asked questions

What does Omeicos Therapeutics do?: OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.
Who founded Omeicos Therapeutics?: Omeicos Therapeutics was founded by Robert Fischer, Karen Uhlmann, Wolf-Hagen Schunck, John R. Falck in 2013.
Who are Omeicos Therapeutics's investors?: Omeicos Therapeutics's investors include Remiges Ventures, Inc., Forbion, Vesalius Biocapital Partners.
Where is Omeicos Therapeutics headquartered?: Omeicos Therapeutics is headquartered in Berlin, DE.